Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
Aim. To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity. Materials and methods. The study...
Guardado en:
Autores principales: | Alexander Sergeevich Ametov, Elena Nikolaevna Pakus |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8ffa4d0318294f518682a1bd04185873 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010) -
Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
por: Alina Y. Babenko, et al.
Publicado: (2018) -
Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021) -
Efficacy and safety of metformin for the treatment of gestational diabetes: a new approach to the problem
por: Anna I. Sazonova, et al.
Publicado: (2016) -
The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
por: Aleksander Sergeevich Ametov, et al.
Publicado: (2015)